Decreased plasma apelin levels in pubertal obese children

Serkan Tapan1, Emre Tascilar, Ayhan Abaci

  • 1Department of Medical Biochemistry, Gulhane School of Medicine, Ankara, Turkey. serkantapan7@yahoo.com

Insights

Obese children have lower plasma apelin levels compared to nonobese children. Pubertal status significantly influences these apelin levels in pediatric obesity, highlighting its role in metabolic health.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Obesity Research

Background:

  • Apelin peptide is implicated in obesity-related disorders.
  • Plasma apelin levels in obese children have not been previously reported.

Purpose of the Study:

  • To investigate plasma apelin levels in obese children.
  • To compare apelin and adiponectin levels between obese and nonobese children.
  • To evaluate the impact of pubertal status on these levels.

Main Methods:

  • Measured plasma apelin, adiponectin, and high-sensitivity C-reactive protein (hs-CRP).
  • Included 32 obese and 40 nonobese children.
  • Assessed the influence of pubertal status on measured biomarkers.

Main Results:

  • Obese children exhibited significantly lower plasma apelin, adiponectin, and HDL cholesterol.
  • Obese children showed higher hs-CRP, triglycerides, insulin, and HOMA-IR.
  • Apelin level differences were significant only during the pubertal period.

Conclusions:

  • Plasma apelin levels are reduced in childhood obesity.
  • Pubertal status is a critical determinant of plasma apelin levels in children.
Abstract

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...